IBL is dedicated to the systematic study and application of knowledge and understanding to determine the means by which a recognized and specific need may be met. Our end result is the development toward the production of useful materials, devices, and systems or methods, including design, development, and improvement of prototypes and new processes to meet these specific requirements in enhancing better life expectancy.

 IBL intends to take R&D to another dynamic level in Africa and be a pioneer in championing methods and researches in the biotechnology industry.

IBL AND CLINICAL TRIALS

 In furtherance of its research and development’s programme, IBL plans to set up a world class clinical trial facility in Keffi, Nasarawa state.

 Clinical trials are forms of investigation conducted in human subjects intended to discover or verify the safety and/or efficacy of an investigational product(s), before it is licensed for general use by the public. It is a critical step in the development process of any new drug, vaccine or treatment.

 When completed, this comprehensive 20-bed in-patient facility fully equipped with state-of-the-art facilities, will offer Nigerian doctors and researchers the opportunity to take part in leading edge globally recognized clinical research.  It will also allow medical research organizations, pharmaceutical and biotechnology companies to generate valuable intellectual property and investment from being able to conduct clinical trials using this facility. Eventually, it will improve patient’s access to the most promising new drugs and treatment services for their benefits.

 Arrangements are currently in place to adequately train all the staff that will be involved in this sensitive area of service delivery. It will invariably serve as a nucleus for training and capacity building for young scientists and researchers in Nigeria, and the continent at large.

 Presently, IBL in partnership with the International partnership for microbicide (IPM U. S. A.) is conducting a cross sectional HIV incidence study in preparation for a phase III clinical trials in microbicide, here in Nigeria.

 IPM & IBL (Power point presentation) click to view